Drug Discovery of Nucleos(t)ide Antiviral Agents: Dedicated to Prof. Dr. Erik De Clercq on Occasion of His 80th Birthday

Clinical significance of chemokine receptor antagonists

(2020) Miao Miao et al.   Expert Opinion on Drug Metabolism & Toxicology

Rapidly decreased HBV RNA predicts responses of pegylated interferons in HBeAg-positive patients: a longitudinal cohort study

(2020) Min Zhang et al.   Hepatology International

Therapeutic options for the 2019 novel coronavirus (2019-nCoV)

(2020) Guangdi Li et al.   NATURE REVIEWS DRUG DISCOVERY

Adverse events of nucleos(t)ide analogues for chronic hepatitis B: a systematic review

(2020) Raquel Scherer de Fraga et al.   JOURNAL OF GASTROENTEROLOGY

Synthesis of 4′-Substituted-2′-Deoxy-2′-α-Fluoro Nucleoside Analogs as Potential Antiviral Agents

(2020) Mahesh Kasthuri et al.   MOLECULES

Discovery, Design, Synthesis, and Application of Nucleoside/Nucleotides

(2020) Katherine Seley-Radtke   MOLECULES

Comparative Antiviral Activity of Remdesivir and Anti-HIV Nucleoside Analogs against Human Coronavirus 229E (HCoV-229E)

(2020) Keykavous Parang et al.   MOLECULES

Clinical characteristics of older and younger patients infected with SARS-CoV-2

(2020) Zhiguo Zhou et al.   Aging-US

Uracil-Containing Heterodimers of a New Type: Synthesis and Study of Their Anti-Viral Properties

(2020) Anna A. Maslova et al.   MOLECULES

Danoprevir for the Treatment of Hepatitis C Virus Infection: Design, Development, and Place in Therapy

(2020) Miao Miao et al.   Drug Design Development and Therapy

Repurposing existing drugs for the treatment of COVID-19/SARS-CoV-2 infection: A review describing drug mechanisms of action

(2020) Hassan Yousefi et al.   BIOCHEMICAL PHARMACOLOGY

Similar risk of hepatocellular carcinoma during long-term entecavir or tenofovir therapy in Caucasian patients with chronic hepatitis B

(2020) Zhili Wen et al.   JOURNAL OF HEPATOLOGY

Post-Catalytic Complexes with Emtricitabine or Stavudine and HIV-1 Reverse Transcriptase Reveal New Mechanistic Insights for Nucleotide Incorporation and Drug Resistance

(2020) Nicole Bertoletti et al.   MOLECULES

Synthesis and Antiviral Evaluation of 3′-Fluoro-5′-norcarbocyclic Nucleoside Phosphonates Bearing Uracil and Cytosine as Potential Antiviral Agents

(2020) Pierre-Yves Geant et al.   MOLECULES

Synthesis of New Imidazopyridine Nucleoside Derivatives Designed as Maribavir Analogues

(2020) Georgios Papadakis et al.   MOLECULES

Novel Nucleoside Analogues as Effective Antiviral Agents for Zika Virus Infections

(2020) Marcella Bassetto et al.   MOLECULES

Identification of a novel long-acting 4’-modified nucleoside reverse transcriptase inhibitor against HBV

(2020) Nobuyo Higashi-Kuwata et al.   JOURNAL OF HEPATOLOGY

Novel Therapeutics for Epstein–Barr Virus

(2019) Graciela Andrei et al.   MOLECULES

Propargylated Purine Deoxynucleosides: New Tools for Fluorescence Imaging Strategies

(2019) Akkaladevi Venkatesham et al.   MOLECULES

New HSV-1 Anti-Viral 1′-Homocarbocyclic Nucleoside Analogs with an Optically Active Substituted Bicyclo[2.2.1]Heptane Fragment as a Glycoside Moiety

(2019) Tănase et al.   MOLECULES

Current and emerging non-nucleoside reverse transcriptase inhibitors (NNRTIs) for HIV-1 treatment

(2019) Yali Wang et al.   Expert Opinion on Drug Metabolism & Toxicology

Investigation of 5’-Norcarbocyclic Nucleoside Analogues as Antiprotozoal and Antibacterial Agents

(2019) Anastasia Khandazhinskaya et al.   MOLECULES

Probing the Effects of Pyrimidine Functional Group Switches on Acyclic Fleximer Analogues for Antiviral Activity

(2019) Mary K. Yates et al.   MOLECULES

The evolution of nucleoside analogue antivirals: A review for chemists and non-chemists. Part 1: Early structural modifications to the nucleoside scaffold

(2018) Katherine L. Seley-Radtke et al.   ANTIVIRAL RESEARCH

Role of tenofovir alafenamide (TAF) in the treatment and prophylaxis of HIV and HBV infections

(2018) Erik De Clercq   BIOCHEMICAL PHARMACOLOGY

Tanovea® for the treatment of lymphoma in dogs

(2018) Erik De Clercq   BIOCHEMICAL PHARMACOLOGY

Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance

(2018) Norah A. Terrault et al.   HEPATOLOGY

96 weeks treatment of tenofovir alafenamide vs . tenofovir disoproxil fumarate for hepatitis B virus infection

(2018) Kosh Agarwal et al.   JOURNAL OF HEPATOLOGY

Impact of antiviral prophylaxis in adults Epstein-Barr Virus-seronegative kidney recipients on early and late post-transplantation lymphoproliferative disorder onset: a retrospective cohort study

(2018) Simon Ville et al.   TRANSPLANT INTERNATIONAL

No Resistance to Tenofovir Alafenamide Detected through 96 Weeks of Treatment in Patients with Chronic Hepatitis B Infection

(2018) Andrea L. Cathcart et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

The evolution of antiviral nucleoside analogues: A review for chemists and non-chemists. Part II: Complex modifications to the nucleoside scaffold

(2018) Mary K. Yates et al.   ANTIVIRAL RESEARCH

EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection

(2017) Pietro Lampertico et al.   JOURNAL OF HEPATOLOGY

Tenofovir alafenamide (TAF) as the successor of tenofovir disoproxil fumarate (TDF)

(2016) Erik De Clercq   BIOCHEMICAL PHARMACOLOGY

Approved Antiviral Drugs over the Past 50 Years

(2016) Erik De Clercq et al.   CLINICAL MICROBIOLOGY REVIEWS

C-Nucleosides To Be Revisited

(2015) Erik De Clercq   JOURNAL OF MEDICINAL CHEMISTRY

Curious Discoveries in Antiviral Drug Development: The Role of Serendipity

(2015) Erik De Clercq   MEDICINAL RESEARCH REVIEWS

AMD3100/CXCR4 Inhibitor

(2015) Erik De Clercq   Frontiers in Immunology

An Odyssey in antiviral drug development—50 years at the Rega Institute: 1964–2014

(2015) Erik De Clercq   Acta Pharmaceutica Sinica B

Tenofovir Alafenamide Vs. Tenofovir Disoproxil Fumarate in Single Tablet Regimens for Initial HIV-1 Therapy

(2014) Paul E. Sax et al.   JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES

Advances in the development of nucleoside and nucleotide analogues for cancer and viral diseases

(2013) Lars Petter Jordheim et al.   NATURE REVIEWS DRUG DISCOVERY

Where rilpivirine meets with tenofovir, the start of a new anti-HIV drug combination era

(2012) Erik De Clercq   BIOCHEMICAL PHARMACOLOGY

Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up study

(2012) Patrick Marcellin et al.   LANCET

A 40-Year Journey in Search of Selective Antiviral Chemotherapy*

(2011) Erik De Clercq   Annual Review of Pharmacology and Toxicology

The clinical potential of the acyclic (and cyclic) nucleoside phosphonates. The magic of the phosphonate bond

(2011) Erik De Clercq   BIOCHEMICAL PHARMACOLOGY

Preexposure Chemoprophylaxis for HIV Prevention in Men Who Have Sex with Men

(2010) Robert M. Grant et al.   NEW ENGLAND JOURNAL OF MEDICINE

The AMD3100 story: The path to the discovery of a stem cell mobilizer (Mozobil)

(2009) Erik De Clercq   BIOCHEMICAL PHARMACOLOGY

Highlights in the Discovery of Antiviral Drugs: A Personal Retrospective

(2009) Erik De Clercq   JOURNAL OF MEDICINAL CHEMISTRY

The history of antiretrovirals: key discoveries over the past 25 years

(2009) Erik De Clercq   REVIEWS IN MEDICAL VIROLOGY

GS-9219--A Novel Acyclic Nucleotide Analogue with Potent Antineoplastic Activity in Dogs with Spontaneous Non-Hodgkin's Lymphoma

(2008) H. Reiser et al.   CLINICAL CANCER RESEARCH

Treatment of locally recurrent epstein–barr virus-associated nasopharyngeal carcinoma using the anti-viral agent cidofovir

(2008) Tomokazu Yoshizaki et al.   JOURNAL OF MEDICAL VIROLOGY

The discovery of antiviral agents: Ten different compounds, ten different stories

(2008) Erik De Clercq   MEDICINAL RESEARCH REVIEWS

Tenofovir Disoproxil Fumarate versus Adefovir Dipivoxil for Chronic Hepatitis B

(2008) Patrick Marcellin et al.   NEW ENGLAND JOURNAL OF MEDICINE